News
Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...
The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...
Nicole Verdun, MD, super office director of the FDA’s Office of Therapeutic Products (OTP) and her deputy Rachael Anatol, PhD ...
Curay, who stepped into the role as the agency’s top drug regular in January, is departing in July, according to an email ...
When Americans imagine the future, it always has a lot to do with flying cars, robot housekeepers, and just about anything ...
Stocktwits on MSN3d
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel DataShares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the ...
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...
The Alliance for Regeneration Medicine (ARM), a trade group that represents more than 400 members companies across 25 ...
Pharmaceutical Technology on MSN3d
FDA cell and gene therapy director exit increases ‘volatility’ for sectorNicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...
In the wake of Marks' exit, FDA commissioner Marty Makary, M.D., named Vinay Prasad, M.D., to head up CBER. In addition to that title, Prasad recently added the title of "chief medical and science ...
Capricor stock drops as FDA cancels advisory meeting on Duchenne therapy; leadership changes and regulatory tensions fuel uncertainty.
The FDA has launched a review of clinical trials that plan to send American citizens' living cells to 'hostile' countries – ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback